$FOSUN PHARMA(02196)$https://www.channelnewsasia.com/asia/taiwan-biontech-vaccines-available-earlier-expected-2136461?cid=FBcna&fbclid=IwAR17fJi37NaG6Gl6fBiWF-zTzUnQrdbkIVB3ABQ67BDwpgaqvVKUl8oWA2UFosun is dealer for Pfizer/BioNTech mRNA COVID vaccine in China. Potentially very profitable.
I get it why some may be tempted to sell but there is atleast one big news near term which has not been priced in yet- China approval, which can be expected any day now. Expert panel has given go-ahead ot his vaccine, its in administrative review stage. I believe with the latest delta surge in China, they dont want to delay a decision on this. $FOSUN PHARMA(02196)$ factory capacity is 1 billion doses so we're looking at$BioNTech SE(BNTX)$ $10-15 billion sales territory when that happens.
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a China-based company principally engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company operates its businesses through five segments. The Pharmaceuticals segment is primarily engaged in the research, development, production and sales of pharmaceuticals. The Medical Devices and Diagnostics segment is primarily engaged in the research, development, production and sales of medical devices and diagnostic products. The Healthcare Services segment is primarily engaged in the provision of healthcare services and hospital management. The Pharmaceutical Distribution and Retail segment primarily engages in the distribution and retail of pharmaceuticals and medical devices. The Company also operates the Other segment. The Company mainly operates its businesses in the domestic market and overseas markets.
08-25
Interim Report
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHSENDED 30 JUNE 2026
PROPOSED SPIN-OFF LISTING OF FOSUN ADGENVAX (A SUBSIDIARY OF THE COMPANY) ON THE HONG KONG STOCK EXCHANGE; NOTICE OF EGM AND NOTICE OF H SHAREHOLDERS' CLASS MEETING